NCT Number: NCT02553473
Six Versus Two Weeks Treatment With Doxycycline in Lyme Neuroborreliosis
Comparison of Doxycycline 200 mg once daily for six weeks versus Doxycycline 200 mg once daily for two weeks + placebo for four weeks. Primary objective is to answer the question "is two weeks doxycycline treatment (currently suggested treatment) at least as effective as six weeks doxycycline treatment in Lyme Neuroborreliosis?".Key secondary objectives are to provide a better understanding of the pathogenesis and long-term complaints, and to search for new biomarkers in Lyme Neuroborreliosis (LNB) by collecting clinical data, blood, and cerebrospinal fluid (CSF) in a biobank for future research
Endpoints:
Primary endpoint: Improvement on a composite clinical score from inclusion to six months after ended treatment defined as clinical score at inclusion minus clinical score at six months.
Secondary endpoints: Improvement on a composite clinical score 12 months after ended treatment. Fatigue Severity Scale (FSS),Patient Health Questionnaire (PHQ-15), Short Form 36 (SF-36) and blood and CSF findings at inclusion, after 6 and 12 months.
The study design is a multicenter, non-inferiority, randomized, penta-blind, placebo-controlled trial. 120 patients will be included from approximately 8 Norwegian hospitals.
Main inclusion criteria are neurological symptoms suggestive of LNB without other obvious reasons, one or both of a) Cerebrospinal fluid pleocytosis (>5 leukocytes/mm3) b) intrathecal Bb antibody Production and signed informed consent. Safety assessments during the trial: Comparison of clinical outcome six months after end of treatment between the two treatment groups. Subjective experiences and blood tests including hematology and biochemistry for four weeks after ended treatment.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Neurological symptoms suggestive of LNB without other obvious reasons and one or both of
- Cerebrospinal fluid pleocytosis ≥5 leukocytes pr mm3
- Intrathecal Bb antibody production
- Signed informed consent
Exclusion criteria
- Age less than 18 years
- Pregnancy, breast-feeding
- Adverse reaction to tetracyclines
- Treatment with cephalosporin, penicillin, or tetracycline the last 14 days
- Serious liver or kidney disease that contraindicates use of doxycycline
- Lactose intolerance
- Need to use medications contraindicated according to Summary of Product Characteristics of the Investigational Medicinal Product
Treatment and study plan
Placebo
DrugPrimary outcomes
-
Difference in Composite Clinical Score From Inclusion to Six Months After Ended Treatment
Time frame: Six months after end of treatment.
Clinical change on composite clinical score (CCS) defined as score at inclusion minus score at 6 months after treatment.CCS consisted of 32 variables,scored from 0 to 2 points.Minimum 0 points,maximum 64 points.High scale score indicated worse outcome.
Variables scored:Malaise,Fatigue,Headache,Neck and/or back pain,Abdominal and/or breast pain,Arm pain,Leg pain,Generalised pain located to joints and/or muscles,Memory and/or concentration problems,Other,Facial palsy,Paresis of the eye muscles,Reduced hearing,Other cranial neuropathies,Cervical radicular sensory findings,Cervical radicular paresis,Thoracic radicular sensory findings,Lumbar radicular sensory findings,Lumbar radicular paresis,Non-radicular sensory findings,Non-radicular paresis,Other,Central findings in one extremity,Central findings in a hemi pattern,Central findings in both legs,Central findings in all extremities,Gait ataxia,Dysphasia/aphasia, Nystagmus,Involuntary movement including tremor,Cognitive impairment,Other.
Sponsors and collaborators
Lead sponsor
Sorlandet Hospital HF
Other Gov
Registry information
Official study title
Six Versus Two Weeks Treatment With Doxycycline in Lyme Neuroborreliosis; a Multicenter, Non-inferiority, Penta-blind, Randomized Trial
Important dates
- Study start
- 2015
- Primary completion
- 2020
- Study completion
- 2021
- First posted
- Sep 17, 2015
- Registry last updated
- Jan 23, 2024
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Impact on the Quality of Life and Persistent Symptoms of Patients Away From Diagnosed and Treated Neuroborreliosis
NCT05742139
Bacterial Infections, Bacterial Infections and Mycoses
Besançon, France
View Trial DetailsEffect of Intravenous Ceftriaxone and Oral Doxycycline for Lyme Neuroborreliosis
NCT00138801
Bacterial Infections, Bacterial Infections and Mycoses
Kristiansand, Vest-Agder, Norway
View Trial DetailsStudy Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis
NCT03010228
Bacterial Infections, Bacterial Infections and Mycoses
La Mesa, California, United States
View Trial DetailsClinical Manifestations and Long-Term Outcome in Early Lyme Neuroborreliosis
NCT04653558
Bacterial Infections, Bacterial Infections and Mycoses
Ljubljana, Slovenia
View Trial Details